ARTICLE | Company News
Micromet, AstraZeneca deal
November 9, 2009 8:00 AM UTC
Micromet bought out all remaining rights to blinatumomab (MT103) and all other bispecific T cell engager (BiTE) antibodies for hematological cancers from AstraZeneca's MedImmune LLC subsidiary, endin...